CPIX Cumberland Pharmaceuticals Inc.
Financings ·
Cumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected.
Cumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold.
Apotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs.
Cumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it.
Cumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn.
The sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. Its primary target markets are hospital acute care, gastroenterology and oncology. It promotes its approved products through hospital, field and oncology sales divisions in the United States, and works with a network of international partners to register and provide its medicines in their countries. Its FDA-approved brands include Acetadote (acetylcysteine) injection, Caldolor (ibuprofen) injection, Kristalose (lactulose) oral solution, Sancuso (granisetron) transdermal, Vaprisol (conivaptan) injection, Vibativ (telavancin) injection and Tacilia. Its ifetroban product candidate is in Phase II programs for systemic sclerosis and idiopathic pulmonary fibrosis, and the company has announced breakthrough results in a clinical study of ifetroban in cardiomyopathy associated with Duchenne muscular dystrophy.
| Product or program | What it is | Stage |
|---|---|---|
| Acetadote (acetylcysteine) injection | Treatment of acetaminophen poisoning | approved by the FDA |
| Caldolor (ibuprofen) injection | Treatment of pain and fever | approved by the FDA |
| Vibativ (telavancin) injection | Treatment of serious bacterial infections, including pneumonia and skin infections | approved by the FDA |
| Vaprisol (conivaptan) injection | Raises serum sodium levels in hospitalized patients with hyponatremia | approved by the FDA |
| Kristalose (lactulose) oral solution | Prescription laxative for the treatment of constipation | approved by the FDA |
| Ifetroban | Product candidate studied in systemic sclerosis, pulmonary fibrosis and Duchenne cardiomyopathy | Phase II programs underway |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.6 million | $4.8 million |
| Net income (loss) | -$2.8 million | -$6.5 million |
| Cash from operations | $4.9 million | -$612,186 |
| Cash and equivalents | $11.4 million | $18.0 million |
Our latest story on this, dated Jul 13, 2026: "Cumberland Pharmaceuticals declares $1.50 special dividend, authorizes $5 million buyback". The story links the filing or release it is based on. Read the story.
Cumberland Pharmaceuticals Inc. trades under the ticker CPIX on NASDAQ.
Cumberland Pharmaceuticals Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cumberland Pharmaceuticals Inc. is 1087294. Its filings are on SEC EDGAR.
14,983,107 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Cumberland Pharmaceuticals Inc. under United States.
Our directory classifies Cumberland Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cumberland Pharmaceuticals Inc. is US2307701092.
aibio.space lists Cumberland Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as TN.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. Its primary target markets are hospital acute care, gastroenterology and oncology.
Acetadote (acetylcysteine) injection: Treatment of acetaminophen poisoning Stage: approved by the FDA.
Caldolor (ibuprofen) injection: Treatment of pain and fever Stage: approved by the FDA.
Cumberland Pharmaceuticals Inc. reported a net loss of $2.8 million for the fiscal year ended Dec 31, 2025, and generated $4.9 million of cash from operations, per its annual report to the SEC.
$5.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Announced a share repurchase program. SEC Form 8-K (Items 8.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,5.02,8.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form PREM14A. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio